https://www.selleckchem.com/products/smi-4a.html
es in knee function or swelling were seen. Therapeutic study with level of evidence I. Therapeutic study with level of evidence I.Dose reduction of biologics for psoriasis could contribute to lower drug exposure. This study evaluated a one-step, tightly controlled, biologic dose reduction strategy in a prospective daily practice cohort. In patients with psoriasis with low disease activity using adalimumab, etanercept or ustekinumab for at least 6 months, the dosing interval was prolonged with 33%. Patients could return to their normal do
Like
Comment
Share
